Not a good buy right now for an impatient entry: short-term momentum is weakening (MACD negative and expanding) and price is below the key pivot (277.3).
Long-term story remains attractive (Vyjuvek growth + multiple registrational programs), but near-term setup suggests better risk/reward closer to support (263.4, then 254.9).
Options positioning and analyst actions are bullish, but the technical tape and pattern-based forward odds skew to near-term downside, so I would not buy at 269 pre-market today.
Technical Analysis
Trend structure is still bullish on longer timeframes: SMA_5 > SMA_20 > SMA_200.
Near-term momentum is bearish: MACD histogram -2.514 (below 0) and negatively expanding → selling pressure is increasing.
RSI_6 = 34.84 (weak/near-oversold zone): downside may be getting stretched, but not yet a confirmed reversal signal.
Key levels: Pivot 277.3 (overhead), resistance 291.2 then 299.7; support 263.4 then 254.9.
Price (269.13) is below pivot and closer to support → suggests the market is in a pullback phase rather than a fresh breakout.
Quant/pattern read (similar candlesticks): 1D ~flat, but next week skewed negative (-15.7%), arguing against chasing today.
Sentiment is call-skewed: OI put/call = 0.40 and volume put/call = 0.19 → traders are positioning more bullish than bearish.
Volatility is elevated: 30D IV 53.28 vs historical vol 40.68; IV percentile 74.5 → options are pricing meaningful event/price risk.
Volume is active vs typical: today’s option volume ~61.9% of 30D average (already, pre-market context), suggesting attention/positioning into upcoming catalysts (notably earnings).
Pipeline upside: registrational programs KB803/KB801/KB407 targeting potential 2028 launches; KB801 (neurotrophic keratitis) repeatedly highlighted as a major value driver.
CF program encouragement: KB407 Phase 1/2 update viewed as robust/proof-of-concept by several analysts.
Earnings upcoming (QDEC 2025 on 2026-02-18 pre-market) can act as a catalyst if Vyjuvek trajectory surprises to the upside.
Neutral/Negative Catalysts
for higher conviction per analyst commentary, leaving room for skepticism/volatility.
Financial Performance
Latest reported quarter: 2025/Q3.
Revenue: $97.8M, +16.65% YoY → continued top-line growth.
Profitability surged: Net income $79.365M, +192% YoY; EPS $2.66, +192.31% YoY.
Notable upgrades in targets: Goldman to $327 (from $206), Clear Street to $338 (from $288), BofA to $318 (from $288), TD Cowen to $306 (from $202), Citi to $320 (from $309).
Wall Street pros: Vyjuvek growth durability, leverageable infrastructure for ophthalmology programs, and multiple pipeline shots on goal.
Wall Street cons/risks: biggest near-term binary revolves around upcoming data/timelines (especially NK/KB801 tracking) and the need for additional functional endpoints for KB407 (e.g., FEV1) to solidify conviction.
Influential/political trading check: no recent congress trading data available; hedge funds and insiders are reported neutral with no significant recent trend.
Wall Street analysts forecast KRYS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for KRYS is 229.25 USD with a low forecast of 198 USD and a high forecast of 278 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Analyst Rating
Wall Street analysts forecast KRYS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for KRYS is 229.25 USD with a low forecast of 198 USD and a high forecast of 278 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
1 Hold
0 Sell
Strong Buy
Current: 267.640
Low
198
Averages
229.25
High
278
Current: 267.640
Low
198
Averages
229.25
High
278
Goldman Sachs
Buy
maintain
$206 -> $327
AI Analysis
2026-01-30
Reason
Goldman Sachs
Price Target
$206 -> $327
AI Analysis
2026-01-30
maintain
Buy
Reason
Goldman Sachs raised the firm's price target on Krystal Biotech to $327 from $206 and keeps a Buy rating on the shares. Krystal Biotech is positioning for near-term growth with three registrational programs, KB803, KB801, and KB407, targeting potential 2028 launches, the analyst tells investors in a research note. Ophthalmic programs are viewed as de-risked and highly leverageable on existing Vyjuvek infrastructure, while KB407 shows promise in cystic fibrosis but requires FEV1 data for conviction, the firm says.
Clear Street
Buy
maintain
$288 -> $338
2026-01-26
Reason
Clear Street
Price Target
$288 -> $338
2026-01-26
maintain
Buy
Reason
Clear Street raised the firm's price target on Krystal Biotech to $338 from $288 and keeps a Buy rating on the shares. The shares have moved higher on Vyjuvek growth and building appreciation of its pipeline opportunities, the analyst tells investors in a research note. The firm says "most consistent excitement among investors" is being placed on Krystal's potential in the neurotrophic keratitis market with KB801. Clear cites increased estimates for KB801 for the target bump.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for KRYS
